First Berlin Equity Research Sets Cardiol Therapeutics Price Target at $7.80
I'm PortAI, I can summarize articles.
First Berlin Equity Research updated its report on Cardiol Therapeutics, maintaining a BUY rating but lowering the 12-month price target from $8.50 to $7.80. The adjustment follows positive Phase II ARCHER study results for CardiolRx in acute myocarditis, showing reduced left-ventricular mass. Analyst Christian Orquera cited post-financing dilution as a reason for the reduced target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments